Multicentre, randomised, open label study comparing a 'scheduled steroid reduction strategy' versus a free steroid reduction strategy (physician's usual practice for reducing steroids) in patients with active RA [rheumatoid arthritis] treated with Humira [adalimumab] 40 mg EOW [every other week] + MTX [methotrexate] during 9 months

Trial Profile

Multicentre, randomised, open label study comparing a 'scheduled steroid reduction strategy' versus a free steroid reduction strategy (physician's usual practice for reducing steroids) in patients with active RA [rheumatoid arthritis] treated with Humira [adalimumab] 40 mg EOW [every other week] + MTX [methotrexate] during 9 months

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2007

At a glance

  • Drugs Adalimumab; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top